Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Johnson & Johnson ( JNJ - Analyst Report ) is all set to complete its acquisition of Synthes, Inc. on June 14, 2012. The company, which received Federal Trade Commission (FTC) approval recently, will be acquiring Synthes for a total purchase price of approximately $19.7 billion in cash and stock.
For each share of Synthes, the shareholder will be entitled to receive CHF 55.65 in cash and 1.7170 shares of Johnson & Johnson common stock.
Antitrust approval from the European Commission was granted on April 19, 2012. Meanwhile, the FTC asked Johnson & Johnson to sell its system for treating distal radius wrist fractures. Johnson & Johnson said that it will be selling its entire trauma portfolio, including DVR, to Biomet. The sale is scheduled to go through later this month.
Johnson & Johnson announced that its wholly owned Irish subsidiary, Janssen Pharmaceutical, has signed a $12.9 billion accelerated share repurchase (ASR) programs with two investment bankers. The shares purchased under the ASR agreements, along with cash on hand from Janssen Pharmaceutical, will be used towards the purchase consideration for the Synthes deal.
With the company announcing the share buyback program and the financial structure for the deal, Johnson & Johnson now expects the Synthes acquisition to be accretive to earnings instead of dilutive as expected earlier. Earlier, the company had said that it expects the deal to be dilutive by 22 cents per share in 2012.
However, with the financial structure in place, the company now expects the acquisition to boost 2012 adjusted earnings by 3-5 cents per share. Meanwhile, 2013 earnings are expected to be boosted by 10-15 cents per share due to the acquisition.
Johnson & Johnson expects to incur charges of $1.1 billion in 2012 related to the acquisition. We expect to get more details when the company reports second quarter results on July 17, 2012. At that time, we believe the company will update its 2012 earnings guidance of $5.07 - $5.17 per share. The Zacks Consensus Estimate for 2012 and 2013 is $5.11 and $5.43 per share, respectively.
Through the Synthes acquisition, Johnson & Johnson is looking to strengthen its medical device portfolio. The products of both companies should complement each other.
Synthes has a strong global footprint with manufacturing facilities in the US, Europe and China and a solid pipeline of new products and technologies. Synthes’ global sales came in at $3.97 billion in 2011, with US sales coming in at $2.14 billion.
We currently have a Neutral recommendation on Johnson & Johnson, which carries a Zacks #3 Rank (short-term Hold rating).
Read the full Analyst Report on JNJ